MedPath

Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)

A Study of BGM0504 in Overweight or Obese Participants

Phase 1
Recruiting
Conditions
Overweight or Obese
Interventions
First Posted Date
2025-04-09
Last Posted Date
2025-04-09
Lead Sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Target Recruit Count
28
Registration Number
NCT06920056
Locations
🇨🇳

The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine (Yunnan Provincial Hospital of Traditional Chinese Medicine), Kunming, Yunnan, China

A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2025-01-14
Last Posted Date
2025-01-15
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
36
Registration Number
NCT06772779
Locations
🇺🇸

Celerion (Site 0001), Tempe, Arizona, United States

Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair

Phase 4
Recruiting
Conditions
Mitral Valve Repair Surgery
Interventions
First Posted Date
2024-12-18
Last Posted Date
2024-12-18
Lead Sponsor
Guangdong Provincial People's Hospital
Target Recruit Count
384
Registration Number
NCT06738992
Locations
🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects

Phase 1
Active, not recruiting
Conditions
Type 2 Diabetes
Interventions
First Posted Date
2024-12-09
Last Posted Date
2025-01-07
Lead Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Target Recruit Count
57
Registration Number
NCT06723691
Locations
🇨🇳

The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

First Posted Date
2024-11-13
Last Posted Date
2024-12-27
Lead Sponsor
Sanofi
Target Recruit Count
20
Registration Number
NCT06686628
Locations
🇩🇪

Investigational Site Number : 2760001, Berlin, Germany

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients with Assist Device

Phase 4
Recruiting
Conditions
Bleeding
Clot Blood
Interventions
First Posted Date
2024-10-23
Last Posted Date
2024-10-23
Lead Sponsor
Columbia University
Target Recruit Count
128
Registration Number
NCT06655376
Locations
🇺🇸

Columbia Irving Medical Center, New York, New York, United States

The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis

Completed
Conditions
End-Stage Kidney Disease (ESKD)
Non-valvular Atrial Fibrillation (NVAF)
Venous Thromboembolism (VTE)
Interventions
First Posted Date
2024-09-20
Last Posted Date
2024-11-05
Lead Sponsor
Abu Dhabi Health Services Company
Target Recruit Count
67
Registration Number
NCT06606275
Locations
🇦🇪

SEHA Tawam Hospital, Al Ain, Abu Dhabi, United Arab Emirates

Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction

Phase 4
Not yet recruiting
Conditions
Left Ventricular Thrombus
Acute Myocardial Infarction
Interventions
First Posted Date
2024-07-23
Last Posted Date
2024-07-29
Lead Sponsor
Karolinska Institutet
Target Recruit Count
212
Registration Number
NCT06515730

The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)

Not Applicable
Active, not recruiting
Conditions
Heart Diseases
Cardiovascular Diseases
Aortic Valve Stenosis
Heart Valve Diseases
Valve Disease, Aortic
Interventions
First Posted Date
2024-06-10
Last Posted Date
2025-04-06
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
352
Registration Number
NCT06449469
Locations
🇩🇰

Aarhus University Hospital, Skejby, Aarhus, Denmark

🇩🇰

Rigshospitalet, Copenhagen, Denmark

A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2024-03-28
Last Posted Date
2025-05-08
Lead Sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Target Recruit Count
57
Registration Number
NCT06335134
Locations
🇨🇳

West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath